These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19410458)

  • 1. Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.
    Wang C; Barluenga S; Koripelly GK; Fontaine JG; Chen R; Yu JC; Shen X; Chabala JC; Heck JV; Rubenstein A; Winssinger N
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3836-40. PubMed ID: 19410458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
    Shen G; Wang M; Welch TR; Blagg BS
    J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Hsp90 chaperone: synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90.
    Day JE; Sharp SY; Rowlands MG; Aherne W; Workman P; Moody CJ
    Chemistry; 2010 Mar; 16(9):2758-63. PubMed ID: 20087915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
    Huang KH; Veal JM; Fadden RP; Rice JW; Eaves J; Strachan JP; Barabasz AF; Foley BE; Barta TE; Ma W; Silinski MA; Hu M; Partridge JM; Scott A; DuBois LG; Freed T; Steed PM; Ommen AJ; Smith ED; Hughes PF; Woodward AR; Hanson GJ; McCall WS; Markworth CJ; Hinkley L; Jenks M; Geng L; Lewis M; Otto J; Pronk B; Verleysen K; Hall SE
    J Med Chem; 2009 Jul; 52(14):4288-305. PubMed ID: 19552433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HSP90 with pochoximes: SAR and structure-based insights.
    Barluenga S; Fontaine JG; Wang C; Aouadi K; Chen R; Beebe K; Neckers L; Winssinger N
    Chembiochem; 2009 Nov; 10(17):2753-9. PubMed ID: 19856365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
    Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
    Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.
    Barluenga S; Wang C; Fontaine JG; Aouadi K; Beebe K; Tsutsumi S; Neckers L; Winssinger N
    Angew Chem Int Ed Engl; 2008; 47(23):4432-5. PubMed ID: 18435518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.
    Kinzel L; Ernst A; Orth M; Albrecht V; Hennel R; Brix N; Frey B; Gaipl US; Zuchtriegel G; Reichel CA; Blutke A; Schilling D; Multhoff G; Li M; Niyazi M; Friedl AA; Winssinger N; Belka C; Lauber K
    Oncotarget; 2016 Jul; 7(28):43199-43219. PubMed ID: 27259245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10-hydroxycamptothecins.
    He X; Lu W; Jiang X; Cai J; Zhang X; Ding J
    Bioorg Med Chem; 2004 Aug; 12(15):4003-8. PubMed ID: 15246077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies.
    Day JE; Sharp SY; Rowlands MG; Aherne W; Lewis W; Roe SM; Prodromou C; Pearl LH; Workman P; Moody CJ
    Chemistry; 2010 Sep; 16(34):10366-72. PubMed ID: 20661961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100.
    Kim SH; Tangallapally R; Kim IC; Trovato R; Parker D; Patton JS; Reeves L; Bradford C; Wettstein D; Baichwal V; Papac D; Bajji A; Carlson R; Yager KM
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5254-7. PubMed ID: 26483201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
    Edsall AB; Agoston GE; Treston AM; Plum SM; McClanahan RH; Lu TS; Song W; Cushman M
    J Med Chem; 2007 Dec; 50(26):6700-5. PubMed ID: 18052315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally active purine-based inhibitors of the heat shock protein 90.
    Biamonte MA; Shi J; Hong K; Hurst DC; Zhang L; Fan J; Busch DJ; Karjian PL; Maldonado AA; Sensintaffar JL; Yang YC; Kamal A; Lough RE; Lundgren K; Burrows FJ; Timony GA; Boehm MF; Kasibhatla SR
    J Med Chem; 2006 Jan; 49(2):817-28. PubMed ID: 16420067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.